cibinetide peptide is a synthetic 11 amino acid peptide - Survodutidepeptide ARA290 confers neuroprotective effects on diabetic rodent retina Cibinetide Peptide: A Novel Approach to Tissue Repair and Neuropathy Management

ARA 290peptidedosage chart The realm of therapeutic peptides is continuously expanding, offering innovative solutions for a range of medical conditions. Among these, the cibinetide peptide, also widely recognized as ARA 290, has garnered significant attention for its unique properties and potential applications, particularly in the areas of nerve regeneration and managing inflammatory disordersCibinetide/ARA290 peptide. This synthetic peptide is engineered from a specific segment of erythropoietin (EPO) and holds promise for conditions where traditional treatments fall shortA small peptide that activates the innate repair receptorto induce anti-inflammatory and tissue repair mechanisms. Other Names: pHSBP, Cibinetide..

Understanding Cibinetide: The Science Behind the Peptide

Cibinetide is an 11-amino acid peptide that distinguishes itself from its parent molecule, EPO, by its lack of hematopoietic (blood-forming) effects. This crucial distinction allows for its therapeutic use without the associated risks of stimulating red blood cell production.Cibinetide Improves Corneal Nerve Fiber Abundance ... - IOVS Instead, cibinetide functions as an erythropoietin receptor agonist, specifically targeting the tissue-protective receptor, often referred to as the Innate Repair Receptor (IRR). By activating this receptor, ARA 290 initiates a cascade of biological responses aimed at promoting anti-inflammatory and tissue repair mechanisms. Its molecular weight is approximately 1258.

The scientific community has extensively researched the mechanisms of cibinetidePeptide. Comment:Cibinetide(ARA 290) is an engineeredpeptidethat mimics the 3 dimensional structure of the helix B surface domain of erythropoietin (EPO).. Studies indicate that it is an engineered peptide that mimics the three-dimensional structure of the helix B surface domain of EPO. This specific structure is key to its ability to bind to the EPO/CD131 heteroreceptor complex, thereby triggering beneficial cellular responses. Unlike full-length EPO, ARA 290 is a nonerythropoietic analog of erythropoietin (EPO), meaning it can deliver the protective benefits without the unwanted blood-related side effects.

Therapeutic Potential: Addressing Pain, Neuropathy, and Inflammation

One of the most compelling applications of the cibinetide peptide lies in its capacity to provide effective and long-term pain relief, particularly following peripheral nerve damage. Research has demonstrated that cibinetide has shown efficacy in alleviating symptoms associated with small fiber neuropathy, leading to reduced neuropathic pain and improved nerve function.A small erythropoietin derived non-hematopoietic peptide ... This is achieved through its potent anti-inflammatory and tissue repair properties, which help to mitigate cellular damage and promote healing.Cibinetide: Uses, Interactions, Mechanism of Action

Furthermore, cibinetide has exhibited promising results in conditions involving inflammation and tissue damage. Studies have shown that ARA290 confers neuroprotective effects on diabetic rodent retina, a critical finding for managing diabetic complications. It achieves this by reducing retinal thinning and pro-inflammatory stimuli, while simultaneously preserving neural retinal function. Moreover, both cibinetide and EPO ameliorated the clinical course of experimental colitis in mice, resulting in improved weight gain and survival, highlighting its potential in inflammatory bowel diseases. The anti-inflammatory actions of cibinetide extend to dampening innate immune cell functions, contributing to its overall therapeutic profile.

Clinical Evidence and Applications

The development of cibinetide has progressed through various research stages, with several clinical trials exploring its potential. For instance, studies have investigated its use in sarcoidosis patients with interstitial lung disease, aiming to assess its safety and efficacy. The compound has also been evaluated for its ability to regenerate nerve fibers and improve symptoms in various conditions.Cibinetide:a EPO receptor agonists Drug, Initially developed by Araim Pharmaceuticals, Inc., Now, its global highest R&D status is Preclinical, ...

Preclinical research has provided significant insights into its capabilities. Cibinetide has demonstrated significant nerve regrowth, as assessed by different measures of nerve fiber regeneration. In one notable study, cibinetide significantly increased small nerve fiber abundance in the cornea and skin, suggesting a disease-modifying effect.Cibinetide (ARA290)is a nonerythropoietic peptideengineered from erythropoietin,, and used for neurological disease treatment. This capacity for nerve regeneration is a cornerstone of its therapeutic appeal.

The health benefits of ARA-290 (cibinetide) are primarily linked to its ability to reduce cell and tissue inflammation and promote repairCibinetide (ARA290)is a nonerythropoietic peptideengineered from erythropoietin,, and used for neurological disease treatment.. Patients utilizing cibinetide have often reported improved nerve function, reduced neuropathic pain, and faster recovery from tissue damage. Its potential applications are broad, including the treatment of neurological disorders, and it has even been explored for its potential neurotrophic and antidepressant effectsPeptide. Comment:Cibinetide(ARA 290) is an engineeredpeptidethat mimics the 3 dimensional structure of the helix B surface domain of erythropoietin (EPO)..

Key Attributes of the Cibinetide Peptide:

* Structure: An 11-amino acid peptide derived from the helix B surface peptide domain of erythropoietin (EPO).

* Mechanism: Activates the Innate Repair Receptor (IRR) and acts as an erythropoietin receptor agonist.Cibinetide - Drug Targets, Indications, Patents - Synapse

* Key Properties: Anti-inflammatory, immunomodulatory, tissue repair, and neuroprotective作者：NM Winicki·2023·被引用次数：6—ARA290 (cibinetide),an 11-aa non-hematopoietic peptide sequencewithin the cardioprotective domain of erythropoietin, mediates tissue protection by reducing ....

* Distinction from EPO: Non-hematopoietic, meaning it does not stimulate red blood cell production.

* Synonyms: ARA 290, HBSP (Helix B Surface Peptide), pHSBP, Pyroglutamate HBSPA small erythropoietin derived non-hematopoietic peptide ....

* Applications: Treatment of neuropathic pain, peripheral nerve damage, small fiber neuropathy, sarcoidosis, and potentially other inflammatory and degenerative conditions.cibinetide | Ligand page

In conclusion, the cibinetide peptide (ARA 290) represents a significant advancement in the field of peptide therapeutics. Its ability to promote tissue repair, reduce inflammation, and facilitate nerve regeneration offers a promising avenue for managing a spectrum of debilitating conditions, providing hope for improved patient outcomes and a better quality of life.